Senior Manager, Pricing and Contracts
About the job
- A bachelor's degree in Market Research, Marketing, Project Management, or Supply Chain Management is required.
- At least five years of experience in the job offered or as a Pricing Analyst in the generic pharmaceutical business, covering Rx or OTC products, is required.
- Knowledge of pricing analysis, contract negotiation, product costing, contract compliance including MFN clauses, SAP ERP, Power BI, Salesforce, pricing strategy development, revenue growth, and margin expansion is required.
- Review and analyze pharmaceutical pricing and rebate structures across the generic pharmaceutical business for Rx and OTC products, and prepare pricing models for new business opportunities using product-costing insights to recommend competitive pricing.
- Prepare profitability analyses for RFPs, price adjustments, and new product launches.
- Conduct pricing analysis using advanced Microsoft Excel and maintain and manage pricing data in SAP ERP, Power BI, and Salesforce.
- Develop and implement pricing and contract standard operating procedures to support adherence across Sales, Finance, and Customer Service.
- Compile monthly commercial operations status summaries for C-suite executives.
- Research and analyze market opportunities and profitability to support pricing strategy development, revenue growth, and margin expansion initiatives.
- Review pricing accuracy in SAP ERP and iContracts to ensure contract alignment and accurate customer pricing.
- Coordinate internal and external customer pricing communications.
- Ensure customer pricing complies with contractual terms, including management of MFN clause compliance and support for contract negotiations.
About the company
Granules India makes APIs, PFIs, and finished dosages, using large-scale, vertically integrated plants that control production from base chemicals to final medicines. Its products include common off-patent APIs like Paracetamol, Ibuprofen, Metformin, and Guaifenesin, and it is expanding into more complex areas such as MUPS, oncology, and peptide therapies with US FDA approvals. The company differentiates itself through full vertical integration, large scale, and a global manufacturing footprint that supports both contract manufacturing and its own branded products, offering supply security and cost competitiveness. Its goal is to deliver reliable, affordable medicines to customers worldwide while growing capabilities in complex therapies and pursuing sustainable practices like green chemistry.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
2014
Get referred to Granules
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q3 FY26 revenue rose 22% to INR 1,388 crores, led by North America and Europe.
- July 2026 inspections at Genome Valley and Chantilly improved regulatory optionality and capacity.
- Europe grew 151% year-on-year in FY26, while peptide CDMO opened a new revenue vertical.
What critics are saying
- FDA warning letter dated February 26, 2025 threatens Gagillapur product approvals until remediation closes.
- Reuters on April 9, 2026 reported record-keeping and contamination concerns still burden management.
- Any second FDA action at Gagillapur can shut U.S. launches and damage Granules' generics franchise.
What makes Granules unique
- Granules integrates APIs, PFIs, and dosages, preserving cost control across the value chain.
- February 2025 Senn Chemicals acquisition adds peptide CDMO capabilities and European regulated-market access.
- Granules shipped in 80 countries and won 94 approvals by August 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours